Genmab — September 2019
-
Fred være med det. Det skal nok komme.
-
Søde drømme.
https://m.youtube.com/watch?v=qeMFqkcPYcg -
Flere millioner på vej til Florian S. Brug dem på køb af Genmab aktier Florian. ;-). https://penge.borsen.dk/artikel/1/387776/nestor_i_dansk_biotek_staar_til_at_blive_forgyldt_efter_lundbecks_koebstilbud_pragtfuldt_at_blive_valideret_med_saadan_et_koebstilbud.html?utm_source=forside&utm_campaign=nyhed_01
-
-
Han er ellers om muligt den eneste der kan virke mere positiv omkring Genmab, end selv den kære Jan.
-
-
Finally, Genmab A/S (GMAB) is reiterated as a Buy with a $24 price target at H.C. Wainwright this morning which had this to say about their valuation methodology.
We use a discounted cash flow based approach to valuing 2.0% terminal growth rate, 8.0% discount rate and 23% effective tax rate.
-
We assign a 90% probability of approval to DARZALEX in smoldering MM; a 95% probability to ARZERRA in relapsing-remitting multiple sclerosis (RR-MS); an 85% probability to teprotumumab; a 20% probability to enapotamab vedotin in 35% probabilities of approval to tisotumab vedotin for cervical cancer and ovarian cancer, respectively.”
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind